NAD+ precursor treatment prevents cardiomyopathy but disrupts erythroid maturation in mitochondrial progeria
Cell Reports · 2026
DOI: 10.1016/j.celrep.2026.117849 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2026. Verfasst von Nahid A Khan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Research Programs Unit, Stem Cells and Metabolism, University of Helsinki, 00290 Helsinki, Finland. Electronic address: nahid.khan@helsinki.fi. Hauptthemen laut MEDLINE: NAD, Progeria, Niacinamide, Mitochondria. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Council of Finland.
Abstract (Originalsprache)
Nicotinamide adenine dinucleotide (NAD+) plays a central role in energy metabolism, and its decline is linked to various degenerative diseases. While NAD+ restoration holds therapeutic promise, its long term, tissue-specific consequences remain poorly understood. We investigated effects of nicotinamide riboside (NR) supplementation for "mutator" mice manifesting mitochondrial progeria. Our results reveal strikingly divergent outcomes: in proliferative bone marrow, NR-treated mutators show reductive stress with accumulation of NADH/NADPH, altered amino acid, nucleotide, folate levels, and impaired heme biosynthesis. In blood, erythrocyte maturation defects are aggravated, exacerbating anemia. Conversely, in postmitotic cardiac tissue, NR enhanced contractility, reduces stress response markers and normalized metabolic profile. These findings indicate that while beneficial for heart, chronic NAD+ boosting can compromise erythrocyte maturation in the context of mitochondrial disease. The data emphasize importance of evaluating systemic effects of NAD+ boosting therapies beyond the primary affected tissues and development of tissue-specific metabolic interventions for degenerative diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Programs Unit, Stem Cells and Metabolism, University of Helsinki, 00290 Helsinki, Finland. Electronic address: nahid.khan@helsinki.fi.
- Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland.
- Research Programs Unit, Stem Cells and Metabolism, University of Helsinki, 00290 Helsinki, Finland.
- Department of Biomedical Sciences, University of Lausanne, 1005 Lausanne, Switzerland.
- Department of Biochemistry and Developmental Biology, University of Helsinki, 00290 Helsinki, Finland.
- Research Programs Unit, Stem Cells and Metabolism, University of Helsinki, 00290 Helsinki, Finland; Wihuri Research Institute, Helsinki, Finland; Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä,…
Förderung
- Research Council of Finland
Zitieren
APA
Khan, N. A., Ahlqvist, K., Pradhan, S., Landoni, J., Jackson, C., Zhaivoron, A., Kivelä, R., Euro, L., & Suomalainen, A. (2026). NAD+ precursor treatment prevents cardiomyopathy but disrupts erythroid maturation in mitochondrial progeria. Cell Reports. https://doi.org/10.1016/j.celrep.2026.117849
Vancouver
Khan NA, Ahlqvist K, Pradhan S, Landoni J, Jackson C, Zhaivoron A, et al. NAD+ precursor treatment prevents cardiomyopathy but disrupts erythroid maturation in mitochondrial progeria. Cell Reports. 2026. doi:10.1016/j.celrep.2026.117849
BibTeX
@article{Khan2026,
author = {Khan, Nahid A and Ahlqvist, Kati and Pradhan, Swagat and Landoni, Juan and Jackson, Christopher and Zhaivoron, Aleksandra and Kivelä, Riikka and Euro, Liliya and Suomalainen, Anu},
title = {NAD+ precursor treatment prevents cardiomyopathy but disrupts erythroid maturation in mitochondrial progeria},
journal = {Cell Reports},
year = {2026},
doi = {10.1016/j.celrep.2026.117849}
}
EUVIMED